# Comparison of Metformin, Repaglinide or the Combination of Both in Subjects With Type 2 Diabetes

> **NCT01465152** · PHASE4 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 182 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** metformin
- **DRUG:** repaglinide

## Key facts

- **NCT ID:** NCT01465152
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-03-06
- **Primary completion:** 2004-10-21
- **Final completion:** 2004-10-21
- **Target enrollment:** 182 (ACTUAL)
- **Last updated:** 2017-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01465152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01465152, "Comparison of Metformin, Repaglinide or the Combination of Both in Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01465152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*